Therapy Areas: AIDS & HIV
Chung Named to Aditxt Board of Directors
18 June 2021 - - US-based biotech innovation company Aditx Therapeutics, Inc (NASDAQ: ADTX) has appointed Dr. Lauren Chung to its board of directors as an independent director, the company said.

Dr. Chung has over 20 years of healthcare investment management, investment banking, and advisory experience, and is currently a venture partner at Yozma Group Korea.

She is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.

Prior to her current roles, Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners.

Prior to that, Dr. Chung managed healthcare investment portfolios at institutional investment firms. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children's Hospital.

Dr. Chung has published in many leading peer-reviewed scientific journals, and as a current and former director of public and private companies, she brings a valuable perspective for the company's strategy and operations, as well as extensive scientific insights.

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

The company's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.

Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.